US FTC to debate biosimilar competition drivers and barriers
This article was originally published in SRA
Executive Summary
With biologic medicines becoming "the most important" and "fastest growing" sector within the pharmaceutical industry, the Federal Trade Commission wants to ensure there is fair competition when biosimilars, also known as follow-on biologics (FOBs), enter the US marketplace.